ALAnn-Marie Glasø de Lange

Ann-Marie Glasø de Lange

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ann-Marie Glasø de Lange has a total of 353 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acute Inflammatory Biomarkers are Associated with Global Brain Vulnerability and White Matter Hyperintensity Progression after Stroke

    by Eva Birgitte Aamodt, Heidi Vihovde Sandvig, Katinka Nordheim Alme, Anne-Brita Knapskog, Lars T. Westlye, Ann-Marie G. de Lange, Tom Eirik Mollnes, Torgeir Wethal, Ingvild Saltvedt, Mona Kristiansen Beyer

    BackgroundSystemic inflammation is a crucial component of the acute response to stroke and is associated with poor clinical outcomes. However, its connection to long-term structural brain changes as a pathophysiological explanation for poor outcomes remains incompletely understood.MethodsA total of 241 stroke patients (44.8% women) were included from the Norwegian Cognitive Impairment After Stroke (Nor-COAST) study, with a mean age of 72.8 years and a mean NIHSS score of 3.1. Inflammatory biomarkers were collected from blood during the acute phase (median 4 days after stroke). MRI was performed during the acute stroke phase of the stroke and at 18- and 36-month follow-up, including measures of white matter hyperintensity (WMH) volume, global and hippocampal gray matter volume, and brain age gap (BAG). Relationships between inflammatory biomarkers and brain measures were assessed using linear mixed-effects models.ResultsHigher levels of IL-2, IL-6, MIP-1α, MIP-1β, and IP10 were associated with lower baseline global gray matter volume and higher baseline BAG. IL-1RA, IL-4, IL-5, IL17A, TCC, bFGF, and G-CSF were associated with WMH progression over 36 months. No inflammatory biomarker was associated with baseline hippocampal volume, whereas bFGF and G-CSF were associated with greater hippocampal volume decline over time.ConclusionAcute systemic inflammation after stroke was associated with signs of brain atrophy and white matter damage, characteristics of cerebral atherosclerotic and small vessel disease, which are risk factors for subsequent cerebrovascular events and vascular dementia. In contrast, evidence for an association with hippocampal volume, a hallmark of Alzheimer’s disease, was limited.

  • Open Access

    Genetic Exploration of Depression Onset in Females from Menarche to Menopause

    by Hannah Oppenheimer, Maria Viejo-Romero, Louise Schindler, Arielle Crestol, Dennis van der Meer, Christopher Rayner, Jared Gichohi Maina, Lars T. Westlye, Ann-Marie G de Lange, David M Howard, et al.

    Depression risk in females is markedly elevated during hormonal transitions such as menarche, the perinatal period, and menopause; yet the genetic basis of depression onset during these windows remains uncharacterized. We conducted GWAS meta-analyses (including the X chromosome) in females from Generation Scotland and UK Biobank, running the first GWAS of depression onset around menarche (ncases = 3,089; ncontrols = 25,558) and around natural menopause (ncases = 3,754; ncontrols = 14,079), and the largest female-specific GWAS of continuous age at onset of depression (N = 29,735). We identified one locus for depression onset around menarche and two for depression onset around menopause, including one mapping onto CDKAL1, a gene implicated in metabolic disorders, and no genome-wide significant findings for continuous age at onset. Genetic correlation analyses revealed moderate to strong positive correlations among depression onset around menarche, around menopause, and postpartum depression (rg = 0.47-0.95), suggesting possible shared genetic pathways of reproductive-related depressions. Mendelian randomization demonstrated a causal effect of earlier menarche on depression onset around menarche; by contrast, age at menopause did not causally influence depression onset around menopause. Together, these findings establish a partly shared and partly distinct genetic architecture across reproductive-related depression subtypes, implicate possible metabolic pathways in depression onset around menopause, and provide a genetic framework for understanding why hormonal transitions confer differential depression risk across the female lifespan. By shifting focus from lifetime risk to hormonally defined onset windows, this study advances a timing informed genetic framework for understanding sex differences in depression.

  • Open Access

    Longitudinal Associations Between Physical Activity Behavior and Structural Brain MRI Features After Stroke: A Sub-Study From the Nor-COAST Project

    by Geske Luzum, Eva B. Aamodt, Heather Allore, Dag Alnæs, Mona K. Beyer, Ann-Marie G. de Lange, Ingvild Saltvedt, Till Schellhorn, Lars T. Westlye, Torunn Askim, et al.

    Background: Post-stroke physical activity (PA) behavior may partly explain inter-individual differences in cortical and sub-cortical brain volumes and brain age estimates. Objective: To investigate longitudinal associations of post-stroke PA behavior with structural brain MRI features. Methods: Data were from a multicenter longitudinal cohort study. PA estimates were based on accelerometer measurements. Separate linear mixed models assessed average daily step count at 18 and 36 months, and longitudinal PA trajectory groups as measured at 3, 18, and 36 months after stroke, as primary and secondary exposures. Dependent variables included brain age gap (BAG), representing the discrepancy between brain MRI predicted age and chronological age, and MRI-based cortical, hippocampal, and thalamic volumes at 18- and 36 months post-stroke. Models accounted for age, sex, education, stroke severity, intracranial volume, and MRI scanner. Results: We included 146 participants (age, mean [SD]: 70.3 [11.1]; 45.7% female) with predominantly mild strokes. Every +1000 steps/day were associated with −1.15 (95% CI: −1.76 to −0.53) lower BAG, 2.63 mL (95% CI: 0.31-5.00) larger cortical volume, and 0.07 mL (95% CI: 0.03-0.11) larger hippocampal volume. The association between step/day and thalamic volume was curvilinear, with the largest volumes observed at 4700 steps/day. Out of 4 PA trajectory groups, participants in the most active group had −7.44 years (95% CI: −2.86 to −12.01) lower BAG and 0.90 mL (95% CI: 1.48-0.33) larger thalamic volumes than the least active group. Conclusions: Higher PA levels post-stroke were associated with larger brain volumes and younger-appearing brains.

  • Open Access

    Learning diverse and generic representations of the brain with large-scale multi-task pretraining

    by Esten H. Leonardsen, Andreas Dahl, Madelene C. Holm, Ann-Marie de Lange, Edvard O. S. Grødem, Andre F. Marquand, Øystein Sørensen, Emanuel Schwarz, Ole A. Andreassen, Thomas Wolfers, et al.

    Large pretrained models developed and shared by actors with privileged access to data and compute have played a central role in the democratisation of deep learning in a range of domains. Here, we contribute to this endeavour in the field of neuroimaging, by compiling a large dataset of structural magnetic resonance imaging scans (n=114,257) and using them to pretrain a multi-task convolutional neural network to predict age, sex, handedness, BMI, fluid intelligence and neuroticism. Subsequent analyses show that our pretraining approach results in a rich and diverse feature space, implying the model is sensitive to a broad spectrum of nuanced neuroanatomical variation. We also demonstrate the usefulness of the pretrained model by employing it to predict brain age and perform clinical classifications via transfer learning, showing that it consistently outperforms models trained from scratch.


  • Open Access

    Genetic risk for Alzheimer’s disease, and differential trajectories in circulating blood biomarkers in UK Biobank (n=17,817)

    by Donald Lyall, Oluwatobi Oni, Amy McKie, Jack Beazer, Angelina Kancheva, Rachana Tank, Josie Fullerton, Lachlan Gilchrist, Laura Lyall, Saraid McIlvride, et al.

    Understanding pathways from genetic variation to cognitive impairment is critical for dementia prevention, risk stratification and the development of treatments. While genetic risk factors for dementia are known to associate with cross-sectional differences in biomarkers (e.g. lipids) in healthy people, potential influence over longitudinal trajectories is not understood.We leveraged genetic, general health and two-wave biomarker data from n = 17,817 UK Biobank participants. The outcomes were change in 26 common circulating blood biomarkers including inflammatory, cardiometabolic and lipid families. The presence of apolipoprotein (APOE) e4 ‘risk’ and e2 ‘protective’ alleles were tested separately versus ‘neutral’ e3e3 genotype, as were associations of non-APOE polygenic risk for Alzheimer’s disease. Biomarker change values were corrected for baseline levels, age, deprivation, sex, timepoint interval, smoking history, medication history, deprivation, genotyping chip and 10 genetic principal components (fully-adjusted).The average interval between assessments was 4.30 years (standard deviation; SD = 0.92). For e4 (versus e3e3), four associations were significant: accelerated change in total cholesterol, apolipoprotein b (ApoB) and low-density lipoprotein (LDL) each in the direction of poorer health (standardized β range = 0.021 SDs to 0.036 more change relative to e3e3), and c-reactive protein protectively (β = -0.059; all P < 0.001). For e2 allele presence, there were three significant associations: change in ApoB, total cholesterol and LDL in protective directions (β range = -0.057 to -0.090). There were no APOE genotypic interactions with baseline age, sex, or medication history, nor significant findings associated with non-APOE (Alzheimer’s disease) polygenic risk.APOE e genotype significantly modifies particularly lipid trajectories across time – most strongly ApoB levels. This adds nuance to lipids as a dementia risk factor, and, clinically, suggests more frequent lipid assessments in e4 carriers in that context. Our findings provide a plausible partial biological explanation for APOE’s progressive influence on neurocognitive health.

  • Open Access

    A Bayesian analysis of diagnostic timelines across Alzheimer's disease, frontotemporal dementia, and other neurodegenerative conditions

    by Ananthan Ambikairajah, David Foxe, Ann‐Marie G. de Lange, James Carrick, Sau Chi Cheung, Velandai K. Srikanth, Yun Tae Hwang, Rebekah M. Ahmed, James R. Burrell, Olivier Piguet

    INTRODUCTION: Timely diagnosis is crucial for managing neurodegenerative conditions. This study investigated whether time from symptom onset to diagnosis differs by clinical syndrome and sex.METHODS: This retrospective, cross‐sectional study included 591 participants with Alzheimer's disease (AD), frontotemporal dementia (FTD) subtypes (behavioral variant FTD [bvFTD], semantic dementia [SD], and progressive non‐fluent aphasia), logopenic progressive aphasia (LPA), and syndromes associated with movement disorders (corticobasal syndrome, FTD with motor neuron disease [FTD‐MND], and progressive supranuclear palsy). Bayesian regression models were used to compute diagnostic timelines.RESULTS: Compared to AD (3.35 years; 95% credible interval [CrI]: 3.03–3.72), SD and bvFTD had additional delays of 9.7 (95% CrI: 1.96–20.64) and 14.82 months (95% CrI: 6.94–25.42), respectively, while FTD‐MND was shorter by 11.62 months (95% CrI: −15.7 to −4.68). Men with bvFTD had 23.64 month longer delays than women (95% CrI: 10.35–44.33).DISCUSSION: Diagnostic delays may reflect syndrome‐specific clinical features, diagnostic complexity, and sociocultural factors. Findings highlight the need for improved diagnostic pathways and pre‐clinical biomarkers to facilitate earlier identification.Highlights: Bayesian analyses revealed that diagnostic delays differ by syndrome and sex. Alzheimer's disease (AD) was diagnosed on average 3.35 years after symptom onset. Diagnoses were delayed in semantic and behavioral variant frontotemporal dementia (bvFTD) compared to AD. Men with bvFTD had longer delays than women. Findings support need for improved diagnostic pathways and pre‐clinical biomarkers.


  • Open Access

    Sex differences in polygenic risk for sex-biased brain disorders: Associations with diagnostic status and brain age gap

    by Arielle Crestol, Dennis van der Meer, Nadine Parker, Ann-Marie G de Lange, Espen Hagen, Hannah Oppenheimer, Stener Nerland, Édith Breton, Christian K. Tamnes, Ole A. Andreassen, et al.

    Biological sex influences the prevalence and progression of several brain disorders, yet it remains unclear whether genetic risk interacts with sex in relation to case-control status or brain health. Using data from up to 220 836 females and 187 651 males in the UK Biobank (aged 39–81), we assessed how sex and polygenic risk scores (PRSs) for major depressive disorder (PRS_MDD), Alzheimer’s disease (PRS_AD), schizophrenia (PRS_SCZ), and Parkinson’s disease (PRS_PD) relate to case-control status and MRI-derived brain age gap (BAG) as a proxy of brain health. We tested for sex differences in PRSs and performed regression analyses examining associations between sex, PRSs, and both outcomes. We then compared models with sex-pooled or sex-specific PRSs to explore whether sex-specific PRSs improve predictive accuracy. PRS_SCZ was higher in females, while no other PRSs differed by sex. A significant PRS_AD-by-sex interaction revealed weaker associations with AD case-control status in males than females. Sex-pooled models outperformed sex-specific models for case-control status, apart from PRS_AD, where the female-only PRS_AD model outperformed the sex-pooled model. No sex-by-PRS interactions were significantly associated with BAG. However, male sex, higher PRS_MDD, higher PRS_AD, and lower PRS_PD were associated with higher BAG, indicative of an older brain age. BAG model performance did not differ between sex-pooled and sex-specific PRS models. In summary, while sex-specific PRSs currently offer limited value over sex-pooled scores, the superior performance of the female-specific PRS_AD model suggests that the value of sex-specific PRSs will likely grow with increased statistical power.

  • Open Access

    Shared Cardiovascular Factors and Genetic Overlap of Pregnancy-Related Disorders, Major Depressive Disorder, and Alzheimer’s Disease

    by Hannah Oppenheimer, Alexey Shadrin, Jonas Østerhaug Andersen, Louise Schindler, Arielle Crestol, Ole A. Andreassen, Lars T. Westlye, Ann-Marie G de Lange, Dennis van der Meer, Claudia Barth

    Background: Pregnancy-related disorders, such as hypertensive disorders of pregnancy (HDP) and postpartum depression, have consequences for maternal health, increasing risk for major depressive disorder (MDD) and Alzheimer’s disease (AD). Observational studies show intertwined pathophysiologies and shared cardiovascular factors. However, genetic links of cardiovascular factors with pregnancy-related disorders, MDD, and AD, as well as the genetic mechanisms between the disorders, have not been fully established. Methods: Using summary statistics from female-specific genome-wide association studies, we estimated genetic correlations and causal associations, using Mendelian randomization, between cardiovascular factors (C-reactive protein, HDL-cholesterol, LDL-cholesterol, and triglycerides), pregnancy-related disorders (HDP and postpartum depression), MDD, and AD. For significant associations, BMI, as a known confounder, was included in multivariable Mendelian randomization analyses. Further, we applied causal mixture models (MiXeR) to explore polygenic overlap between pregnancy-related disorders, MDD, and BMI.Results: We found widespread genetic correlations between cardiovascular factors, pregnancy-related disorders, and MDD. Using Mendelian randomization, higher triglycerides and lower HDL-cholesterol were causally linked to higher HDP risk, and higher LDL-cholesterol to higher AD risk. When including BMI, only the effect of triglycerides on HDP remained significant. Trivariate MiXeR estimated substantial polygenic overlap of pregnancy-related disorders with MDD and BMI.Conclusions: Using multiple genetic approaches, our findings indicate some shared cardiovascular factors associated with pregnancy-related disorders, MDD, and AD, partly driven by BMI. BMI should be further explored as a modifiable factor genetically linked to pregnancy-related, mental, and brain disorders. Our findings highlight the relevance of early prevention of genetically interconnected disorders across the female lifespan.

  • Open Access

    Menopausal hormone therapy and the female brain: leveraging neuroimaging and prescription registry data from the UK Biobank cohort

    by Claudia Barth, Liisa Am Galea, Emily G Jacobs, Bonnie H Lee, Lars T Westlye, Ann-Marie G de Lange

    Background and Objectives Menopausal hormone therapy (MHT) is generally thought to be neuroprotective, yet results have been inconsistent. Here, we present a comprehensive study of MHT use and brain characteristics in middle-to older aged females from the UK Biobank, assessing detailed MHT data, APOE ε4 genotype, and tissue-specific gray (GM) and white matter (WM) brain age gap (BAG), as well as hippocampal and white matter hyperintensity (WMH) volumes. Methods A total of 19,846 females with magnetic resonance imaging data were included (current-users = 1,153, 60.1 ± 6.8 years; past-users = 6,681, 67.5 ± 6.2 years; never-users = 12,012, mean age 61.6 ± 7.1 years). For a sub-sample (n = 538), MHT prescription data was extracted from primary care records. Brain measures were derived from T1-, T2- and diffusion-weighted images. We fitted regression models to test for associations between the brain measures and MHT variables including user status, age at initiation, dosage and duration, formulation, route of administration, and type (i.e., bioidentical vs synthetic), as well as active ingredient (e.g., estradiol hemihydrate). We further tested for differences in brain measures among MHT users with and without a history of hysterectomy ± bilateral oophorectomy and examined associations by APOE ε4 status. Results We found significantly higher GM and WM BAG (i.e., older brain age relative to chronological age) as well as smaller left and right hippocampus volumes in current MHT users, not past users, compared to never-users. Effects were modest, with the largest effect size indicating a group difference of 0.77 years (∼9 months) for GM BAG. Among MHT users, we found no significant associations between age at MHT initiation and brain measures. Longer duration of use and older age at last use post menopause was associated with higher GM and WM BAG, larger WMH volume, and smaller left and right hippocampal volumes. MHT users with a history of hysterectomy ± bilateral oophorectomy showed lower GM BAG relative to MHT users without such history. Although we found smaller hippocampus volumes in carriers of two APOE ε4 alleles compared to non-carriers, we found no interactions with MHT variables. In the sub-sample with prescription data, we found no significant associations between detailed MHT variables and brain measures after adjusting for multiple comparisons. Discussion Our results indicate that population-level associations between MHT use, and female brain health might vary depending on duration of use and past surgical history. Future research is crucial to establish causality, dissect interactions between menopause-related neurological changes and MHT use, and determine individual-level implications to advance precision medicine in female health care.


  • Open Access

    Sex-Dependent Effects of Cardiometabolic Health and APOE4 on Brain Age

    by Sivaniya Subramaniapillai, Louise S. Schindler, Paul Redmond, Mark E. Bastin, Joanna M. Wardlaw, Maria Valdés Hernández, Susana Muñoz Maniega, Benjamin Aribisala, Lars T. Westlye, William Coath, et al.

    The aging population is growing faster than all other demographic strata. With older age comes a greater risk of health conditions such as obesity and high blood pressure (BP). These cardiometabolic risk factors (CMRs) exhibit prominent sex differences in midlife and aging, yet their influence on brain health in females vs males is largely unexplored. In this study, we investigated sex differences in relationships between BP, body mass index (BMI), and brain age over time and tested for interactions with APOE ε4 genotype (APOE4), a known genetic risk factor of Alzheimer disease. The sample included participants from 2 United Kingdom-based longitudinal birth cohorts, the Lothian Birth Cohort (1936) and Insight 46 (1946). Participants with MRI data from at least 1 time point were included to evaluate sex differences in associations between CMRs and brain age. The open-access software package brainageR 2.1 was used to estimate brain age for each participant. Linear mixed-effects models were used to assess the relationships between brain age, BMI, BP, and APOE4 status (i.e., carrier vs noncarrier) in males and females over time. The combined sample comprised 1,120 participants (48% female) with a mean age (SD) of 73 (0.72) years in the Lothian Birth Cohort and 71 (0.68) years in Insight 46 at the time point 1 assessment. Approximately 30% of participants were APOE4 carriers. Higher systolic and diastolic BP was significantly associated with older brain age in females only (β = 0.43-0.56, p < 0.05). Among males, higher BMI was associated with older brain age across time points and APOE4 groups (β = 0.72-0.77, p < 0.05). In females, higher BMI was linked to older brain age among APOE4 noncarriers (β = 0.68-0.99, p < 0.05), whereas higher BMI was linked to younger brain age among carriers, particularly at the last time point (β = -1.75, p < 0.05). This study indicates sex-dependent and time-dependent relationships between CMRs, APOE4 status, and brain age. Our findings highlight the necessity of sex-stratified analyses to elucidate the role of CMRs in individual aging trajectories, providing a basis for developing personalized preventive interventions.